 STATEN ISLAND, N.Y., Oct. 4, 2021 PRNewswire -- Acurx Pharmaceuticals, Inc. NASDAQ: ACXP Acurx or the Company, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster were presented on September 29 th at the Infectious Disease Society of America IDSA IDWeekTM 2021 Virtual Conference entitled: An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum GPSSTM Antibiotic, for Patients with Clostridioides difficile Infection. 